Immuno-cancer drug Merck Bavencio passed the Cancer Drugs Benefit Appraisal Committee as an indication for urinary tract epithelial cell cancer.

The HIRA's Cancer Drugs Benefit Appraisal Committee held the 4th meeting in 2022 on the 6th and announced that Bavencio's standards for urinary epithelial cell cancer have been set. Cancer Drugs Benefit Appraisal Committee also set standards only for WM in the case of BeiGene's Brukinsa, which applied for benefits on the same day. It is expected to be used as a monotherapy in adult WM patients who have previously received more than one treatment.

However, Brukinsa failed to set the standard for "single therapy in adult patients with osmotic cel